<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03770689</url>
  </required_header>
  <id_info>
    <org_study_id>MS100036_0020</org_study_id>
    <secondary_id>2018-002275-18</secondary_id>
    <nct_id>NCT03770689</nct_id>
  </id_info>
  <brief_title>Study of Peposertib in Combination With Capecitabine and RT in Rectal Cancer</brief_title>
  <official_title>A Multicenter Study With an Open-label Phase Ib Part Followed by a Randomized, Placebo-controlled, Double-blind, Phase II Part to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of the DNA-PK Inhibitor Peposertib (M3814) in Combination With Capecitabine and RT in Participants With Locally Advanced Rectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMD Serono Research &amp; Development Institute, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck KGaA, Darmstadt, Germany</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>EMD Serono</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of the study is to define maximum tolerated dose (MTD), recommended Phase II&#xD;
      dose (RP2D) safety and tolerability of Peposertib in combination with capecitabine and&#xD;
      radiotherapy (RT).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 20, 2019</start_date>
  <completion_date type="Anticipated">February 17, 2022</completion_date>
  <primary_completion_date type="Actual">June 21, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Experiencing a Dose Limiting Toxicity (DLT)</measure>
    <time_frame>Time from first dose of study drug to end of chemo radiotherapy with a final assessment at 4 weeks post-surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Treatment-related Adverse Events (TEAEs) According to National Cancer Institute Common Terminology Criteria of Adverse Events (NCI-CTCAE) version 5.0</measure>
    <time_frame>Time from first dose of study drug to final assessment at 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Abnormalities (Grade Greater than or equals to (&gt;=) 3) in Laboratory Test Values</measure>
    <time_frame>Time from first study drug to final assessment at 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Markedly Abnormal Vital Sign Measurements</measure>
    <time_frame>Time from first dose of study drug to final assessment at 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Abnormal Electrocardiogram (ECG) Findings</measure>
    <time_frame>Time from first dose of study drug to final assessment at 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With Pathological Complete Response (pCR) and Clinical Complete Response (cCR)</measure>
    <time_frame>Pathology evaluation of specimen after surgery (pCR) and clinical evaluation 1 to 2 weeks prior to surgery (cCR)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free Survival</measure>
    <time_frame>Time from first study drug to final assessment at 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With Pathological Complete Response (pCR)</measure>
    <time_frame>Evaluation of specimen after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With Clinical Complete Response (cCR)</measure>
    <time_frame>Time from first study drug until 1 to 2 weeks prior to surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from Surgery to Local Recurrence and Distant Metastasis</measure>
    <time_frame>Time from surgery to final assessment at 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neoadjuvant Rectal Score</measure>
    <time_frame>Pathology evaluation of specimen after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Drug Concentration (Cmax) of Peposertib</measure>
    <time_frame>Pre-dose, 1, 2, 3 and 4 hour post-dose on Fraction Day (FD1) and Fraction Day 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From Time Zero to Last Sampling Time (tlast) (AUC0-t) of Peposertib</measure>
    <time_frame>Pre-dose, 1, 2, 3 and 4 hour post-dose on Fraction Day 1 and Fraction Day 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Plasma Concentration (tmax) of Peposertib</measure>
    <time_frame>Pre-dose, 1, 2, 3 and 4 hour post-dose on Fraction Day 1 and Fraction Day 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Body Clearance of Drug From Plasma Following Oral Administration (CL/f) of Peposertib</measure>
    <time_frame>Pre-dose, 1, 2, 3 and 4 hour post-dose on Fraction Day 1 and Fraction Day 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution (Vz/f) of Peposertib</measure>
    <time_frame>Pre-dose, 1, 2, 3 and 4 hour post-dose on Fraction Day 1 and Fraction Day 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Terminal Half-life (t1/2) of Peposertib</measure>
    <time_frame>Pre-dose, 1, 2, 3 and 4 hour post-dose on Fraction Day 1 and Fraction Day 9</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Locally Advanced Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Peposertib + Capecitabine + RT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peposertib</intervention_name>
    <description>Participants will receive peposertib at an escalated dose starting from 50 mg once daily 5 days per week in first cohort up to week 6 and for the next cohorts peposertib dose will be determined by the Safety Monitoring Committee (SMC) guided by a Bayesian 2-parameter logistic regression model with overdose control.</description>
    <arm_group_label>Peposertib + Capecitabine + RT</arm_group_label>
    <other_name>M3814</other_name>
    <other_name>MSC2490484A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Participants will receive capecitabine at a dose of 825 milligram per square meter (mg/m^2) twice daily 5 days per week.</description>
    <arm_group_label>Peposertib + Capecitabine + RT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy (RT)</intervention_name>
    <description>Participants will receive RT 50 to 50.4 Gray (Gy) to the tumor area and 45 Gy to the electively irradiated tissues in 25 to 28 fractions (corresponding to 5 to 5.5 weeks).</description>
    <arm_group_label>Peposertib + Capecitabine + RT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants who have an Eastern Cooperative Oncology Group Performance Status less&#xD;
             than or equals to (&lt;=) 1&#xD;
&#xD;
          -  Participants who have histologically confirmed and localized resectable rectal cancer&#xD;
             (Stage 3)&#xD;
&#xD;
          -  Participants who received induction chemotherapy are allowed to be enrolled to this&#xD;
             study except this induction is resulting in clinical complete response (cCR) or tumor&#xD;
             progression&#xD;
&#xD;
          -  Participants who have lower edge of the tumor located in rectum&#xD;
&#xD;
          -  Adequate hematological, hepatic and renal function as defined in the protocol&#xD;
&#xD;
          -  Male participants if they agree to the following during the study intervention period&#xD;
             and for at least 12 weeks after the last dose of study intervention&#xD;
&#xD;
          -  Female participants are eligible if not pregnant or breastfeeding&#xD;
&#xD;
          -  Other protocol defined inclusion criteria could apply&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants with history of any other significant medical disease or psychiatric&#xD;
             conditions that might in the assessment of the Investigator preclude safe&#xD;
             participation in the study&#xD;
&#xD;
          -  Participants with history of difficulty swallowing, malabsorption, or other chronic&#xD;
             gastrointestinal disease or conditions that may hamper compliance and/or absorption of&#xD;
             the study intervention&#xD;
&#xD;
          -  Unstable cardiovascular function within 6 months prior to enrollment&#xD;
&#xD;
          -  Hypertension uncontrolled by medication (ie, systolic blood pressure &gt;= 150 millimeter&#xD;
             of mercury (mmHg) and diastolic blood pressure &gt;= 90 mmHg)&#xD;
&#xD;
          -  Participants with history of other malignant disease within the past 5 years, other&#xD;
             than successfully treated basal carcinoma of the skin or carcinoma in situ of the&#xD;
             cervix&#xD;
&#xD;
          -  Participants with known human immunodeficiency virus positivity, known active&#xD;
             hepatitis (for example, hepatitis B virus or hepatitis C virus), current alcohol&#xD;
             abuse, or cirrhosis&#xD;
&#xD;
          -  Participants with ongoing active infection or treatment with a live attenuated vaccine&#xD;
             within 4 weeks of dosing&#xD;
&#xD;
          -  Participants with concomitant use of H2-blocker or proton pump inhibitors (PPIs) (or&#xD;
             unable to stop at least 5 days prior to the first treatment). Note that calcium&#xD;
             carbonate is acceptable&#xD;
&#xD;
          -  Participation in any interventional clinical study within 28 days prior to Screening&#xD;
             or during participation in this study&#xD;
&#xD;
          -  Other protocol defined exclusion criteria could apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Responsible</last_name>
    <role>Study Director</role>
    <affiliation>Merck KGaA, Darmstadt, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado Cancer Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University - Pediatric Respiratory Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwell Health, Inc</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>10042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center (MSKCC) - New York</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University Clinical Trials Management Office - Ohio State CTMO Parent</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Toledo Medical Center - Hematology/Oncology</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Med. Univ. of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greenville Hospital System University Medical Center (ITOR)</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron - Dept of Oncology</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre - Servicio de Oncologia</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Regional Universitario de Malaga</name>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Valencia - Servicio de Hematologia y Oncologia Medica</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <link>
    <url>https://clinicaltrials.emdgroup.com/en/trial-details/?id=MS100036_0020</url>
    <description>Trial Awareness and Transparency website</description>
  </link>
  <link>
    <url>https://medical.emdserono.com/en_US/home.html</url>
    <description>US Medical Information website, Medical Resources</description>
  </link>
  <link>
    <url>http://www.DDRiver-trials.com</url>
    <description>DDRiver website</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>December 7, 2018</study_first_submitted>
  <study_first_submitted_qc>December 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2018</study_first_posted>
  <last_update_submitted>August 25, 2021</last_update_submitted>
  <last_update_submitted_qc>August 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DNA-PK inhibitor</keyword>
  <keyword>Peposertib</keyword>
  <keyword>capecitabine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>EMD Serono, Inc. is committed to sharing patient-level data and supporting documentation from applicable studies according to company policies. Further information on data sharing and how to request data can be found on our website https://www.emdgroup.com/en/research/our-approach-to-research-and-development/healthcare/clinical-trials/commitment-responsible-data-sharing.html</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

